I am a medical oncology scientist with extensive experience in cancer research and drug development. I head the CRIS Cancer experimental therapeutics unit at Hospital Clinico San Carlos in Madrid; and the preclinical research program at START Madrid at Hospital Fundación Jiménez Díaz.
I have published more than 250 articles and I have a H index of 61.
I have been involved in the preclinical evaluation of novel agents in breast cancer and early clinical development (phase I) of several treatments in different solid tumors.
In our research program our team perform phase I studies in the phase I clinic, we study novel targets through genomic studies in the translational laboratory and we design novel chemical entities guided by AI in our computational chemistry unit.
My personal research has focused on the identification of novel druggable targets, genomic profiles and the study of mechanisms of resistance to new therapeutics including ADCs. More recently we are designing novel antibodies and chemical entities. I have also helped organizations in their global clinical development strategy.
Given my professional background I have extensive experience in all the activities needed for an efficient global early clinical development: from the selection of the lead compound to the demonstration of POC in different patient populations or geographic areas.